Co-morbidity of Cervical Cancer and Its associated factors among HIV-Positive Women on Antiretroviral Therapy in Awi zone, Northwest Ethiopia

Author:

Gashinet Kelemework1,Mohammed Asiya1,Gashinet Addisu2,Shitu Daniel1,Bantie Berihun3,Wudie Gebiyaw1

Affiliation:

1. Bahirdar University

2. University of Gondar

3. Debre Tabor University

Abstract

Abstract

Background Women living with HIV face an increased burden of AIDS-defining malignancies, particularly invasive cervical cancer. The risk of developing cervical cancer (CC) is six times higher in women with HIV compared to their counterparts. However, evidences on the co-morbidity of cervical cancer CC and its associated factors in this high-risk group were scarce in Ethiopia. Therefore, this study aimed to explore the prevalence and factors associated with the co-morbidity of CC in women living with HIV in Northwest Ethiopia. Methods An institution-based cross-sectional study was conducted from January to May 2023, among 583 adult women living with HIV/AIDS in Awi Zone, Northwest Ethiopia. Both primary and secondary data collection methods were carried out to address the objectives of the study. The data were entered into Epi data version 4.6 and exported to SPSS version 26 software for analysis. A binary logistic regression model was fitted to identify factors associated with the outcome variable. Level of statistical significance was declared at p-value < 0.05. Results The comorbidity of cervical cancer among women living with HIV was 24.9% (95% CI: 21.3–28.1). Factors that increased the risk of co-morbidity include a baseline CD4 cell+<200 cell/mm3 (AOR = 3.82, 95% CI: 2.44–5.39), a history of sexually transmitted infections other than HIV (AOR = 3.97, 95% CI: 1.97–5.70), oral contraceptive use (AOR = 2.18, 95% CI: 1.40–3.40), the number of sexual partners (AOR = 2.86, 95% CI: 1.79–4.55), and poor/fair adherence to ART drugs (AOR = 3.25, 95% CI: 1.87–7.43, AOR = 2.81, 95% CI: 1.39–5.64). Conclusion and recommendation In this study, the comorbidity of CC among women living with HIV was found to be high relative to the previous studies in Ethiopia. History of sexually transmitted infection other than HIV, baseline CD4+ cell < 200 cell/mm3, poor and fair adherence, history of long-term oral contraceptive use, and having two and above sexual partners were factors associated with co-morbidity of cervical cancer. Hence, targeted cervical cancer screening by giving due emphasis to those high-risk women, and addressing identifying factors helps to reduce this malignancy.

Publisher

Springer Science and Business Media LLC

Reference76 articles.

1. Center For Disease Control and Prevention (CDC), Basic Information About Cervical Cancer (2022),available from https://www.cdc.gov/cancer/cervical/basic_info/index.htm cited on(8/17/2022).

2. CenterofDiseaseControlandPrevention. (CDC),Inside KnowledgeofCervicalCancerFactsheet(2018),Availablefromhttps://www.cdc.gov/cancer/cervical/pdf/cervical_facts.pdfcitedon(8/19/2022). 2018.

3. Mayo Clinic, Cervical cancer - Symptoms and causes (2021), https://www.mayoclinic.org/diseases-conditions/cervical-cancer/symptoms-causes/syc-20352501cited on (8/17/2022).

4. National Cervical Cancer Coalition(NCCC), Stages of Cervical Cancer,American Sexual Health Association(. 2022),Availablefromhttps://www.nccc-online.org/hpvcervical-cancer/stages-of-cervical-cancer/ citedon(8/21/2022).

5. ESMO, FIRST GLOBAL ESTIMATES OF CERVICAL. CANCER ATTRIBUTABLE TO HIV,Epidemiology/Etiology/Cancer Prevention; Gynaecologic malignancies,the Lancet Global Health (2022),Available fromhttps://www.esmo.org/oncology-news/first-global-estimates-of-cervical-cancer-attributable-to-hivcitedon(8/21/2022)., 2022.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3